Search
Cystic Fibrosis Clinical Trials
A listing of 63 Cystic Fibrosis clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 63
There are currently 63 active clinical trials seeking participants for Cystic Fibrosis research studies. The states with the highest number of trials for Cystic Fibrosis participants are Ohio, California, Florida and New York.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Diagnosis and Treatment of Patients With Cystic Fibrosis
Recruiting
This is an omnibus protocol for studying patients with cystic fibrosis. The main purpose of the study is to obtain samples and data collected during standard clinical care for future research to expand knowledge of the natural history, clinical manifestations (phenotypes) and the genetic variants (genotypes) of cystic fibrosis.
Gender:
ALL
Ages:
Between 4 years and 120 years
Trial Updated:
07/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Cystic Fibrosis, Liver Disease or Abnormalities, Diabetes, Pancreatic Insufficiency (Exocrine and Endocrine)
Natural History of Noncirrhotic Portal Hypertension
Recruiting
Background:
- Noncirrhotic Portal Hypertension (NCPH) is caused by liver diseases that increase pressure in the blood vessels of the liver. It seems to start slowly and not have many warning signs. Many people may not even know that they have a liver disease. There are no specific treatments for NCPH.
Objectives:
- To learn more about how NCPH develops over time.
Eligibility:
- People age 12 and older who have NCPH or are at risk for getting it. In the past year, they cannot have had other... Read More
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
07/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Cystic Fibrosis, Immunologic Deficiency Syndrome, Turner Syndrome, Congenital Hepatic Fibrosis, Idiopathic Non-Cirrhotic Portal Hypertension
Streamlined Treatment of Pulmonary Exacerbations in Pediatrics
Recruiting
The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient pulmonary exacerbations (PEx) in the pediatric CF population.
Gender:
ALL
Ages:
Between 3 years and 18 years
Trial Updated:
07/30/2025
Locations: The Children's Hospital Alabama & University of Alabama at Birmingham, Birmingham, Alabama +32 locations
Conditions: Cystic Fibrosis
A Phase 1 Study Evaluating Safety and Tolerability of RCT2100 in Healthy Participants and in Participants With CF
Recruiting
This is the first-in-human study with RCT2100 and is designed to provide safety and tolerability data for future clinical studies.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/29/2025
Locations: The University of Alabama at Birmingham, Birmingham, Alabama +22 locations
Conditions: Cystic Fibrosis
Genetics of Insulin and Incretins in Cystic Fibrosis
Recruiting
Cystic fibrosis related diabetes (CFRD) is associated with worse CF-relevant outcomes.
The mechanisms underlying CFRD development are not fully understood, but recent evidence suggests Type 2 Diabetes Mellitus (T2DM) mechanisms may be involved and may involve incretins (gut secreted hormones that augment insulin secretion in response to a nutrient load).
This study will examine the prevalence of Genome wide association study (GWAS)-implicated T2DM alleles (including TCF7L2) across the spectrum... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
07/24/2025
Locations: The Children's Hopsital of Philadelphia, Philadelphia, Pennsylvania +1 locations
Conditions: Cystic Fibrosis
Lung Transplant READY CF 2: A Multi-site RCT
Recruiting
Lung transplant is an option for treating end-stage lung disease in cystic fibrosis (CF). In the United States, more people with CF and low lung function die each year than undergo lung transplant. More than half of people with CF who die without a lung transplant were never referred for consideration. Patient preference not to undergo lung transplant may account for 25-40% of decisions to defer referral. Rates of death without transplant are higher for people with CF who are members of marginal... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: University of California at Los Angeles (UCLA), Los Angeles, California +10 locations
Conditions: Cystic Fibrosis
Role of Body Fat Distribution in Metabolic and Pulmonary Decline in Cystic Fibrosis (ORBIT-CF)
Recruiting
Nutrition and body composition, the amount of muscle and fat in the body, has a role in overall health. This study wants to learn more about how nutrition and body composition affects health outcomes like glucose tolerance and lung function in patients with cystic fibrosis (CF) who are ages 16-30 years old. 60 adolescents and young adults with CF will be recruited, and 30 volunteers without cystic fibrosis. A total of 40 of these study participants with CF will be asked to return for annual stud... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
07/17/2025
Locations: University of Alabama at Birmingham (UAB)/Children's of Alabama, Birmingham, Alabama +1 locations
Conditions: Cystic Fibrosis
Sinus Disease in Young Children With Cystic Fibrosis
Recruiting
This is a prospective, observational study examining the impact of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators on chronic rhinosinusitis (CRS) and olfactory dysfunction (OD) in young children with cystic fibrosis (YCwCF). This study involves two groups: children 2-8 years old, inclusive at initial visit, receiving highly effective modulator therapy (HEMT), and a control group of children 2-8 years old, inclusive at initial visit, not receiving HEMT. Out... Read More
Gender:
ALL
Ages:
Between 2 years and 8 years
Trial Updated:
07/14/2025
Locations: Children's Hospital Colorado, Aurora, Colorado +5 locations
Conditions: Cystic Fibrosis in Children, Cystic Fibrosis, Chronic Rhinosinusitis (Diagnosis), Olfactory Disorder, Olfactory Impairment
Natural History of Bronchiectasis
Recruiting
Background:
* Bronchiectasis is a disease characterized by airways that are inflamed, abnormally dilated, and chronically infected. Individuals with bronchiectasis have a history of chronic and recurring respiratory infections. Depending on the underlying cause, these infections may involve the entire respiratory tract, resulting in sinus, ear, and lung disease.
* Bronchiectasis continues to be a significant problem in developing countries and in specific groups of individuals, particularly in... Read More
Gender:
ALL
Ages:
Between 5 years and 100 years
Trial Updated:
07/09/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
Recruiting
The purpose of this study is to evaluate the pharmacokinetics, safety, tolerability and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants with at least 1 triple combination responsive (TCR) mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Gender:
ALL
Ages:
Between 1 year and 11 years
Trial Updated:
07/09/2025
Locations: Children's Hospital of Orange County, Orange, California +37 locations
Conditions: Cystic Fibrosis
Exercise in Child Health
Recruiting
This study is a cooperative investigation funded by the NIH. The project is a collaboration among three major NIH Clinical Translational Science Awardees: 1) UCI (lead site with its affiliate CHOC), 2) Northwestern University (with its affiliate Lurie Children's Hospital), and 3) USC (with its affiliate Children's Hospital of Los Angeles).
There is an increasing number of children who, through medical advances, now survive diseases and conditions that were once fatal, but which remain chronic a... Read More
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
07/07/2025
Locations: University of California, Irvine, Irvine, California
Conditions: Cystic Fibrosis, Sickle Cell Disease, SARS CoV 2 Infection
Role of Genetic Factors in the Development of Lung Disease
Recruiting
This study is designed to evaluate the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung cells of patients with lung disease.
The study will focus on defining the distribution of abnormal genes responsible for processes directly involved in different diseases affecting the lungs of patients and healthy volunteers.
Optional CT Sub-study
The standard CT scan will be compared to the low dose radiation CT s... Read More
Gender:
ALL
Ages:
Between 2 years and 90 years
Trial Updated:
06/27/2025
Locations: Suburban Hospital, Bethesda, Maryland +1 locations
1 - 12 of 63